Results 261 to 270 of about 2,039,151 (340)

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Substance P in the medial amygdala regulates aggressive behaviors in male mice. [PDF]

open access: yesNeuropsychopharmacology
He ZX   +11 more
europepmc   +1 more source

Regulation by Thyroid Hormone of the Concentration of Substance P in the Rat Anterior Pituitary*

open access: bronze, 1984
Neil Aronin   +4 more
openalex   +1 more source

Protein O‐glycosylation in the Bacteroidota phylum

open access: yesFEBS Open Bio, EarlyView.
Species of the Bacteroidota phylum exhibit a unique O‐glycosylation system. It modifies noncytoplasmic proteins on a specific amino acid motif with a shared glycan core but a species‐specific outer glycan. A locus of multiple glycosyltransferases responsible for the synthesis of the outer glycan has been identified.
Lonneke Hoffmanns   +2 more
wiley   +1 more source

Identifying prognostic targets in metastatic prostate cancer beyond AR

open access: yesFEBS Open Bio, EarlyView.
Genome‐wide functional screens combined with a large gene expression database and clinical outcomes can identify new therapeutic vulnerabilities in prostate cancer. Eight potentially druggable targets demonstrated strong dependency in cell lines, were associated with worse prognosis clinically, and showed evidence of protein expression in prostate ...
Emily Feng   +13 more
wiley   +1 more source

Substance P radioimmunoassay

open access: yesJapanese Journal of Pharmacology, 1977
Masanori Otsuka, Noboru Yanaihara
openaire   +2 more sources

Home - About - Disclaimer - Privacy